[Federal Register Volume 78, Number 18 (Monday, January 28, 2013)]
[Notices]
[Pages 5818-5819]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01620]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and
Ischemic Stroke and to Prevent Necrosis
Description of Technology: Sirtuin 2 (SIRT2) inhibitors to reduce
necrosis and, thereby, as novel therapeutics to treat ischemic stroke
and myocardial infarction. Accumulating evidence indicates that
programmed necrosis plays a critical role in cell death during
ischemia-reperfusion. NIH investigators have shown that the NAD-
dependent deacetylase SIRT2 binds constitutively to receptor-
interacting protein 3 (RIP3) and that deletion or knockdown of SIRT2
prevents formation of the RIP1-RIP3 complex in mice. These
investigators also found that genetic or pharmacological inhibition of
SIRT2 blocks cellular necrosis induced by TNF-alpha and RIP1 is a
critical target of SIRT2-dependent deacetylation. Further studies also
showed that the hearts of Sirt2 / mice, or wild-type mice treated with
a specific pharmacological inhibitor of SIRT2, show marked protection
from ischemic injury. These results implicate SIRT2 as an important
regulator of programmed necrosis and indicate that SIRT2 inhibitors may
constitute a novel approach to protect against necrotic injuries,
including ischemic stroke and myocardial infarction.
Potential Commercial Applications:
Novel therapeutics to protect against necrotic injuries.
Novel therapeutics to treat ischemic stroke and myocardial
infarction.
Novel therapeutics to treat diseases in which necrosis is
involved.
Competitive Advantages:
None of the currently available drugs address the necrotic
damage caused due to ischemia and reperfusion.
Using a SIRT2 inhibitor could limit the damage caused by
necrosis and contribute to accelerated recovery in patients suffering
from these conditions.
Development Stage:
Early-stage
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Drs. Nisha Narayan and Toren Finkel (NHLBI)
Publication: Narayan N, et al. The NAD-dependent deacetylase SIRT2
is required for programmed necrosis. Nature. 2012 Dec 13;492(7428):199-
204. [PMID 23201684]
Intellectual Property: HHS Reference No. E-003-2013/0--U.S.
Application No. 61/723,496 filed 17 Nov 2012
Licensing Contact: Suryanarayana (Sury) Vepa, Ph.D., J.D.; 301-435-
5020; vepas@mail.nih.gov
Collaborative Research Opportunity: The NHLBI is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize retinoid-related
orphan receptors (RORs) function in chronic diseases. For collaboration
opportunities, please contact Ms. Peg Koelble at koelblep@mail.nih.gov
or 301-594-4095.
Multivalent Meningiococcal Conjugates and Methods for Preparing
Conjugates
Description of Technology: Among 13 isolated meningococcal
serogroups, A, B, C, W-135 and Y are the most prevalent. There are
three FDA-approved capsular polysaccharide (PS)-based vaccines, one
tetravalent PS vaccine, and two tetravalent conjugate vaccines for
protection against
[[Page 5819]]
meningococcal disease caused by groups A, C, W-135 and Y Neisseria
meningitidis. Group B capsular PS is similar to the PS structure
expressed in certain human tissues, thus making it a poor immunogen.
Furthermore, if used as a vaccine, the possibility exists of it
inducing an autoimmune response. Thus, a need remains to develop
additional meningococcal vaccines, particularly for group B and group X
meningococcal serogroups.
This application claims immunogenic conjugates including at least
one polysaccharide conjugated to a group B factor H binding protein
(fHbp). Also claimed are immunogenic conjugates including at least one
polysaccharide conjugated to a Neisserial surface protein A (NspA).
Additionally, improved methods for preparing conjugates are claimed.
Potential Commercial Applications:
Multivalent meningitis vaccine
Research tool
Competitive Advantages:
Higher vaccine yield
More efficient conjugation method
Lower cost vaccines
Development Stage:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Che-Hung Robert Lee (FDA/CBER), Vavlerian Pinto (EM),
Elizabeth Moran (EM), Robert Burden (EM)
Intellectual Property: HHS Reference No. E-082-2012/0--U.S.
Application No. 61/651,382 filed 24 May 2012.
Related Technologies:
HHS Reference No. E-301-2003/0--U.S. Application No. 13/
243,480 filed 06 Aug 2004, claiming priority to 06 Aug 2003
HHS Reference No. E-085-2005/0--U.S. Patent 8,173,135
issued 08 May 2012; U.S. Application No. 13/440,856 filed 05 Apr 2012,
claiming priority to 17 Mar 2006
Licensing Contact: Peter A. Soukas; 301-435-4646; ps193c@nih.gov
Collaborative Research Opportunity: The FDA/CBER is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate or commercialize
Multivalent Meningiococcal Conjugates and Methods for Preparing
Conjugates. For collaboration opportunities, please contact Che-Hung
Robert Lee at robert.lee@fda.hhs.gov or 301-451-5934.
Enhanced Cancer Therapy Using Photoimmunotherapy (PIT) in Combination
With Anti-Cancer Agents
Description of Technology: The invention is in the field of
Photoimmunotherapy (PIT). More specifically, the invention relates to
antibody-fluorophore conjugates where the antibody is specific for
cancer cells and the fluorophore is IR700 dye. Binding of such
conjugates to targeted cancer cells followed by irradiation with near
infrared light (NIR) was shown to kill cancer cells in a highly
specific manner. Furthermore, the invention discloses that the
therapeutic effect of the PIT conjugate is significantly enhanced by
the administration of one or more anti-cancer agents following the
irradiation step. This is achieved by the markedly rapid accumulation
of the therapeutic agent in the PIT-treated tissue. Also provided in
the invention are wearable devices that incorporate NIR light emitting
diodes (LEDs) and can be used to activate the PIT conjugates.
Potential Commercial Applications: Anti-cancer therapy.
Competitive Advantages:
Highly specific to cancer cells
Do not affect surrounding normal cells
Negligible toxicity
Enhancement of therapeutic effects when administered in
combination with one or more other therapeutic agents
Possible to follow the cell killing process in real time,
using fluorescence lifetime imaging
Development Stage: In vivo data available (animal).
Inventors: Hisataka Kobayashi and Peter L. Choyke (NCI).
Publications:
1. Mitsunaga M, et al. Immediate in vivo target-specific cancer
cell death after near infrared photoimmunotherapy. BMC Cancer 2012 Aug
8;12: 345. [PMID 22873679]
2. Mitsunaga M, et al. Near-infrared theranostic photoimmunotherapy
(PIT): Repeated exposure of light enhances the effect of
immunoconjugate. Bioconjug Chem. 2012 Mar 21;23(3):604-9. [PMID
22369484]
3. Mitsunaga M, et al. Cancer cell-selective in vivo near infrared
photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011
Nov6;17(12):1685-91. [PMID 22057348]
Intellectual Property:
HHS Reference No. E-205-2010/2--PCT Application No. PCT/
US2012/044421 filed 27 Jun 2012
HHS Reference No. E-250-2010/1--U.S. Application No. 13/
180,111 filed 11 Jul 2011
HHS Reference No. E-205-2010/0--U.S. Provisional
Application No. 61/636,079 filed 09 Jul 2010
Licensing Contact: Uri Reichman, Ph.D., MBA; 301-435-4616;
reichmau@mail.nih.gov.
Dated: January 18, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-01620 Filed 1-25-13; 8:45 am]
BILLING CODE 4140-01-P